Home›Aldesleukin›Aldesleukin + Cyp Substrates

Does Aldesleukin Interact with Cyp Substrates?

Aldesleukin and Cyp Substrates have a major drug interaction according to U.S. FDA drug labeling data. Aldesleukin causes release of cytokines that may suppress CYP enzyme activity, resulting in increased exposure of CYP substrates and potential serious adverse reactions. The mechanism involves suppression of cytochrome p-450 enzyme activity via cytokine release. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Aldesleukin Class
Lymphocyte Growth Factor
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Aldesleukin and Cyp Substrates occurs because suppression of cytochrome p-450 enzyme activity via cytokine release. Clinically, this means aldesleukin causes release of cytokines that may suppress cyp enzyme activity, resulting in increased exposure of cyp substrates and potential serious adverse reactions. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Aldesleukin and your doctor is considering prescribing Cyp Substrates (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Aldesleukin(Proleukin)+💊 Cyp Substrates

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Lymphocyte Growth Factor
Drug B class
—
Source
NLP:aldesleukin

What this means in plain English

Aldesleukin causes release of cytokines that may suppress CYP enzyme activity, resulting in increased exposure of CYP substrates and potential serious adverse reactions.

What the FDA label says

"Suppression of cytochrome P-450 enzyme activity via cytokine release"

📖 Source: NLP:aldesleukin

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Aldesleukin and Cyp Substrates against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.